Gilenya® shows long-term efficacy and safety in extension of phase III head-to-head study
New long-term data for Gilenya® (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous treatment. These results, from an extension of the phase III head-to-head TRANSFORMS study, also showed improved efficacy for patients switched to Gilenya from Avonex® (interferon-beta-1a IM), a commonly prescribed MS treatment.
"These data further reinforce our confidence in Gilenya's long-term effectiveness and safety profile. The TRANSFORMS extension study shows that MS patients treated continuously with Gilenya for up to four and a half years demonstrated sustained low levels of clinical and MRI activity," said Tim Wright, Global Head of Development, Novartis Pharma. "Furthermore, patients who switched to Gilenya from interferon beta-1a IM showed a reduction in relapses and improvements in MRI measures in the extension compared to the core study."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
Gilenya® shows long-term efficacy and safety - study
Gilenya® shows long-term efficacy and safety - study
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 2 Replies
- 2560 Views
-
Last post by DIM
-
- 0 Replies
- 1530 Views
-
Last post by NHE
-
- 1 Replies
- 1670 Views
-
Last post by frodo
-
- 0 Replies
- 1907 Views
-
Last post by NHE
-
- 0 Replies
- 1215 Views
-
Last post by frodo
-
- 0 Replies
- 890 Views
-
Last post by frodo
-
- 0 Replies
- 8152 Views
-
Last post by NHE
-
- 0 Replies
- 1564 Views
-
Last post by Tif
-
- 0 Replies
- 1358 Views
-
Last post by NHE